ARTICLE | Company News
Physiomics, ValiRx deal
December 24, 2007 8:00 AM UTC
VAL and PYC completed the first part of a February deal to use PYC's in silico simulations of cellular processes to select cancer targets for VAL's GeneICE oligonucleotide-protein fusion molecules tha...